State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Stanford Medicine

M. Hamilton

CAR T-Cell Therapy Side Effects for Blood Cancers

GRACE

A. Goodman

2024 Updates on Understanding & Managing Immune Effector Cell Toxici…

Indy Hematology Review

D. Reeves

The Improbable History of CAR T-Cells

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

C. June

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments

Elias Jabbour